CN1141957C - Optimized treatment process of frankincense and myrrh - Google Patents
Optimized treatment process of frankincense and myrrh Download PDFInfo
- Publication number
- CN1141957C CN1141957C CNB00131517XA CN00131517A CN1141957C CN 1141957 C CN1141957 C CN 1141957C CN B00131517X A CNB00131517X A CN B00131517XA CN 00131517 A CN00131517 A CN 00131517A CN 1141957 C CN1141957 C CN 1141957C
- Authority
- CN
- China
- Prior art keywords
- frankincense
- myrrh
- beta
- olibanum
- myrrha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004863 Frankincense Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 13
- 235000003717 Boswellia sacra Nutrition 0.000 title abstract 5
- 240000007551 Boswellia serrata Species 0.000 title abstract 5
- 235000012035 Boswellia serrata Nutrition 0.000 title abstract 5
- 240000007311 Commiphora myrrha Species 0.000 title abstract 5
- 235000006965 Commiphora myrrha Nutrition 0.000 title abstract 5
- 235000007265 Myrrhis odorata Nutrition 0.000 title abstract 5
- 239000000341 volatile oil Substances 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 3
- 241000717739 Boswellia sacra Species 0.000 claims description 18
- 241001057584 Myrrha Species 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 9
- 238000005457 optimization Methods 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 11
- 230000000857 drug effect Effects 0.000 abstract description 5
- 238000003384 imaging method Methods 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 206010012735 Diarrhoea Diseases 0.000 abstract description 3
- 206010028813 Nausea Diseases 0.000 abstract description 3
- 206010047700 Vomiting Diseases 0.000 abstract description 3
- 201000006549 dyspepsia Diseases 0.000 abstract description 3
- 230000008693 nausea Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000008673 vomiting Effects 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 2
- 230000006838 adverse reaction Effects 0.000 abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 238000011084 recovery Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Fats And Perfumes (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, in particular to an optimized treatment process of frankincense and myrrh. Is prepared from frankincense and myrrh through pulverizing, dissolving, extracting to obtain volatile components, mixing with beta-CD, wrapping, cooling and suction filtering. The imaging structure of the volatile oil and the beta-CD before and after inclusion is obviously changed, and when the frankincense and the myrrh are used, the irritation to gastrointestinal tracts can be relieved, and the adverse reactions such as abdominal pain, nausea, vomiting, diarrhea, dyspepsia, anorexia and the like can be reduced; thereby further improving the cleanness of the frankincense and the myrrh, improving the drug effect, reducing the adverse reaction and improving the preparation quality.
Description
The present invention relates to tcm field, the optimization process technology of especially a kind of Olibanum, Myrrha.
Olibanum, Myrrha are component raw material comparatively common in the tcm field, its flavour of a drug hardship and gas are turbid, traditional conventional treatment method is comparatively simple, and technology is coarse, records according to version pharmacopeia in 2000, for frying production method makes Olibanum (processed), Myrrha (processed), but its process temperature is difficult to reach relevant temperature, so that zest volatile oil is removed rate is low, and often contains Olibanum in its process, does not have explosive component " string oil ", be difficult for pulverizing, so be difficult to reach the preparation requirement.Therefore the volatile ingredient that it contained is brought into play in the drug effect in gastrointestinal tract, digestive system is had stronger stimulation, usually can cause untoward reaction such as stomachache, nausea,vomiting,diarrhea, dyspepsia, loss of appetite.Its impurities causes the property of medicine impure, hinders the drug effect performance, and influences preparation grade quality.
The object of the present invention is to provide a kind of optimization process technology that improves Olibanum, Myrrha cleannes, raising performance drug effect, reduces untoward reaction, the raising quality of the pharmaceutical preparations.
Purpose of the present invention can realize by following measure:
The optimization process technology of a kind of Olibanum, Myrrha is that Olibanum, Myrrha are crushed into granule, behind petroleum ether dissolution, extraction is until colourless, and the petroleum ether that volatilizees then obtains volatile oil, and (β-CD) aqueous solution stirs with beta-schardinger dextrin-again, cooling, sucking filtration gets final product.
Purpose of the present invention can also realize by following measure:
The optimization process technology of a kind of Olibanum, Myrrha describedly obtains volatile oil and beta-schardinger dextrin-(β-CD) the enclosed molecule ratio is 0.75: 4, and in the time of 50 ℃, stirs and mix inclusion under the condition more than 1 hour.
The present invention has following advantage compared to existing technology:
The present invention obtains behind the volatile ingredient through handling that (β-CD) gives inclusion with beta-schardinger dextrin-with Olibanum, Myrrha, therefore (β-CD) combining imaging arrangement takes place significantly to change at inclusion front and back Olibanum, Myrrha volatile oil and beta-schardinger dextrin-, so Olibanum, Myrrha are when taking, can alleviate the gastrointestinal zest, reduce the generation of untoward reaction such as stomachache, nausea,vomiting,diarrhea, dyspepsia, loss of appetite; Thereby further improve Olibanum, Myrrha cleannes, improve the performance drug effect, reduce untoward reaction, improve the quality of the pharmaceutical preparations.
The present invention also will be further described in conjunction with the embodiments:
1, material and instrument thereof: (β-CD), Yunan, Guangdong dextrin factory produces beta-schardinger dextrin-, and purity is 98%; DF-101 heat collecting type magnetic stirring apparatus; The XF-101BX-x ray diffractometer x, U.S. PerkonElmer company; DSC-ZC type differential scanning calorimeter.
2, technical process: get Olibanum, Myrrha, it be crushed into granule, be dissolution with solvents with petroleum ether after, to colourless, the volatilization petroleum ether obtains volatile oil in the water-bath ventilating kitchen then, and is sealed standby with apparatus,Soxhlet's extracting cut-off; Other gets beta-schardinger dextrin-(β-CD) be dissolved in the distilled water, and place DF-101 heat collecting type magnetic stirring apparatus, and add volatile oil with dissolve with ethanol, keep the temperature of regulation, stir official hour, and supply the water yield, in refrigerator, give cold preservation 24 hours then, with dry nutsch filter sucking filtration, wash with small amount of ethanol, 60 ℃ of dryings 2 hours, weigh, measure oil content, and calculate oily utilization rate and recovery rate.Wherein to the beta-schardinger dextrin-that feeds intake (β-CD) carries out the orthogonal test of three levels with volatile oil enclosed molecule ratio, inclusion temperature, mixing time, result such as following table:
| Project | The inclusion temperature | Mixing time | The enclosed molecule ratio | Recovery rate (%) |
| 1 | 50℃ | 1 hour | 4∶0.75 | 67.37 |
| 2 | 50℃ | 2 hours | 4∶0.5 | 66.67 |
| 3 | 50℃ | 0.5 hour | 4∶1 | 60.80 |
| 4 | 80℃ | 1 hour | 4∶0.5 | 35.50 |
| 5 | 80℃ | 2 hours | 4∶1 | 59.40 |
| 6 | 80℃ | 0.5 hour | 4∶0.75 | 54.30 |
| 7 | 20℃ | 1 hour | 4∶1 | 50.00 |
| 8 | 20℃ | 2 hours | 4∶0.75 | 54.74 |
| 9 | 20℃ | 0.5 hour | 4∶0.5 | 44.44 |
| K1 | 194.84 | 152.87 | 176.41 | T＝492.82 |
| K2 | 148.00 | 180.41 | 146.61 | |
| K3 | 149.18 | 159.64 | 169.80 | |
| R | 45.66 | 20.77 | 29.80 |
Wherein, recovery rate=inclusion complex amount/(beta-schardinger dextrin-(β-CD) input amount+volatile oil input amount)
The result shows.The enclose temperature has remarkable influence to oil content and oily utilization rate.Recovery rate there is not remarkable influence.Proportioning is trembled in throwing and mixing time has remarkable influence to oil content, and oily utilization rate and recovery rate are had remarkable influence.(β-CD) the enclosed molecule ratio is 0.75: 4, and in the time of 50 ℃, stirring mixes inclusion under the condition more than 1 hour best wherein to obtain volatile oil and beta-schardinger dextrin-.
In addition, ((β-CD) inclusion complex adds Arabic smear to the beta-schardinger dextrin-of powder of β-CD) and Olibanum, Myrrha to get beta-schardinger dextrin-respectively, micro-imaging, (β-CD) combine imaging arrangement has tangible difference to can be observed volatile oil and beta-schardinger dextrin-before and after the inclusion, because the change of structure can alleviate this composition to the gastrointestinal zest.
Claims (2)
1, the optimization process technology of a kind of Olibanum, Myrrha is characterized in that Olibanum, Myrrha are crushed into granule, behind petroleum ether dissolution, extraction is until colourless, and the petroleum ether that volatilizees then obtains volatile oil, stirs with the beta-schardinger dextrin-aqueous solution again, cooling, sucking filtration gets final product.
2, the optimization process technology of a kind of Olibanum as claimed in claim 1, Myrrha is characterized in that described volatile oil and beta-schardinger dextrin-enclosed molecule ratio are 0.75: 4, and in the time of 50 ℃, stirs and mix inclusion under the condition more than 1 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB00131517XA CN1141957C (en) | 2000-10-24 | 2000-10-24 | Optimized treatment process of frankincense and myrrh |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB00131517XA CN1141957C (en) | 2000-10-24 | 2000-10-24 | Optimized treatment process of frankincense and myrrh |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1349813A CN1349813A (en) | 2002-05-22 |
| CN1141957C true CN1141957C (en) | 2004-03-17 |
Family
ID=4594694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB00131517XA Expired - Fee Related CN1141957C (en) | 2000-10-24 | 2000-10-24 | Optimized treatment process of frankincense and myrrh |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1141957C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100370997C (en) * | 2005-12-09 | 2008-02-27 | 九寨沟天然药业集团有限责任公司 | Freezing-disintegrating process of boswellia carterii and myrrh |
| ITRM20120043A1 (en) * | 2012-02-08 | 2013-08-09 | Aboca Spa Societa Agricola | FORMULATION FOR IBS. |
| CN107267288A (en) * | 2017-06-17 | 2017-10-20 | 安徽仁之堂药业有限公司 | A kind of highly effective extraction method of Olibanum volatile oil |
-
2000
- 2000-10-24 CN CNB00131517XA patent/CN1141957C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1349813A (en) | 2002-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104857517B (en) | A kind of miscellaneous Shandong amine soft capsule of grace and preparation method thereof | |
| CN1141957C (en) | Optimized treatment process of frankincense and myrrh | |
| CN104367987A (en) | Astragalus mongholicus formulation for veterinary use and preparation method thereof | |
| CN110066350A (en) | Blue or green money willow Polyose extraction and the method for blue or green money willow polysaccharide solid beverage preparation | |
| CN106349319B (en) | The method that hydrolysis asiaticosid prepares asiatic acid | |
| CN101148441A (en) | Andrographolidi natrii bisulfis and preparation method thereof | |
| CN1315500C (en) | Effervescence tablet of Chinese globeflower and its preparation process | |
| CN103126979A (en) | Luteolin solution composition | |
| CN102836133B (en) | Sodium aescinate freeze-dried powder injection and preparation method thereof | |
| CN102626427B (en) | Ginkgo dipyridamole composition and preparation method of preparation thereof | |
| CN101108224A (en) | Plants natural base extractive and formulated product and use thereof | |
| CN111588775B (en) | Belladonna extract and belladonna capsule compound preparation | |
| CN103301468A (en) | High-content luteolin composition | |
| CN102113997A (en) | Domperidone suspension and preparation method thereof | |
| CN103285082B (en) | Medicament composition for treating gynecological inflammation | |
| CN102552419A (en) | Tanreqing dropping pills and preparation method thereof | |
| CN105462784A (en) | Method for preparing alkalescent tea baijiu | |
| JP4574742B1 (en) | Propolis composition | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN100358499C (en) | Xiaoaiping dripping pill for treating various cancers and its preparing method | |
| CN111747912A (en) | Preparation method of diterpenoid compound | |
| CN100363018C (en) | Honeysuckle flower soft capsule and preparation method thereof | |
| CN102772583A (en) | Heat clearing tablet and preparation method thereof | |
| JP7531240B2 (en) | Arabinose and its preparations and uses | |
| CN100358497C (en) | Drop pills of canary-creeper and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |